Product
Supplier
Encyclopedia
Inquiry
Home > Chemicals Market Price & Insight > Ofloxacin Market Price & Analysis > Featured News - Ofloxacin > Zhejiang Pharmaceutical Subsidiary Changhai Pharmaceutical's daptomycin API passed the U.S. FDA on-site inspection
— Share —

Zhejiang Pharmaceutical Subsidiary Changhai Pharmaceutical's daptomycin API passed the U.S. FDA on-site inspection

healthoo 2021-02-18
On February 11, 2021, Changhai Pharmaceutical received a notification letter from the FDA and an on-site inspection report (EIR) issued for this inspection.

Please sign in to view all content or subscribe.

Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.